No Data
No Data
IntelGenx Announces Voting Results on Election of Directors
IntelGenx Announces First Parkinson's Disease Patients Dosed With Montelukast VersaFilm in Phase 2 'MONTPARK' Clinical Trial
SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm has been administered to
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that its co-developer, Chemo Research SL, through its agent and affiliate,
IntelGenx Technologies Corp. (PNK:IGXT) Q4 2023 Earnings Call Transcript
Earnings Call Summary | Intelgenx Technologies Corp.(IGXT.US) Q4 2023 Earnings Conference
The following is a summary of the IntelGenx Technologies Corp. (IGXT) Q4 2023 Earnings Call Transcript:Financial Performance:IntelGenx reported Q4 total revenue of $426,000, a 146% increase compared t
IntelGenx GAAP EPS of -$0.01, Revenue of $0.43M
No Data